|
Vasoactive agent Pikamilon in pigmented retinal abiotrophy
Davydova G.A., Mukha A.I.
[Article in Russian]
Otdel Patologii Setchatki, Mosk. NI Institut Glaznykh Boleznej, Minzdravmedproma Rossii, Moskva Russian Federation
Vestnik Oftalmologii (Russian Federation), 1995, 111/3 (20-22)
Abstract
Eighty patients with pigmented retinal abiotrophy (PRA) and 20 controls were examined.
The perfusion pressure and arteriovenous coefficient are markedly reduced in patients with stages 1-2 PRA, in comparison with controls.
Deterioration of the visual function in patients with stages 3-4 PRA vs. that in stages 1-2 was associated with a more marked reduction of the hemodynamic parameters and the status of ocular vessels.
Pikamilon therapy in a dose of 2 ml of 10% solution once a day intramuscularly for 10 days led to improvement of the visual function and ocular hemodynamics in patients with PRA. Treatment efficacy was higher in patients with disease stages 1-2.
Pikamilon is recommended for the treatment of patients with PRA.
|